Damora Therapeutics
We have no price for Damora Therapeutics since 8 June 2026. It may have been taken over, merged or renamed, so the figures below are from then.
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
We do not have this company's yearly figures yet, so its profit, growth, price and debt cannot be judged here.
Damora Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Damora Therapeutics | No profit yet | ||
 Atai Beckley N.V | No profit yet | ||
 Avalyn Pharma | No profit yet | ||
 Cullinan Therapeutics | No profit yet | ||
 High Tide | No profit yet |
AI analysis
An AI analyst reads Damora Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Profitability
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Growth
- –
- –
- –
- –
- –
Financial health
- –
- –
- –
- –
- –
- –
- –
What analysts expect
- Average price target
- $43.67
- Range
- $40.00 – $46.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | -0.62 | -0.39 | −59.9% |
| Mar 18, 2026 | -3.24 | -0.14 | −2,216.4% |
| Nov 6, 2025 | -2.36 | – | – |
| Aug 5, 2025 | -2.60 | – | – |
| May 8, 2025 | -1.92 | – | – |
| Mar 19, 2025 | -5.22 | -3.12 | −67.3% |
| Nov 1, 2024 | -3.39 | -3.70 | +8.4% |
| Aug 12, 2024 | -4.00 | -8.00 | +50.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Questions about Damora Therapeutics
Is Damora Therapeutics a good stock to buy?
We do not have this company's yearly figures yet, so its profit, growth, price and debt cannot be judged here. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Damora Therapeutics AI analysis
What does Damora Therapeutics do?
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. It is in Medical - Pharmaceuticals.
Who are Damora Therapeutics's competitors?
The largest listed companies in the same industry are Atai Beckley N.V, Avalyn Pharma, Cullinan Therapeutics and High Tide. The peers table on this page compares their profit, growth and price with Damora Therapeutics's.
Prices: daily closes to Jun 8, 2026. Fundamentals: company reports via invest-like data.